In vitro allergy diagnostics are currently based on the detection of specific IgE binding on intact allergens or a mixture thereof. This approach has drawbacks as it may yield false-negative and/or false-positive results. Thus, we reviewed the impact of known B-cell epitopes of food allergens to predict transience or persistence, tolerance or allergy and the severity of an allergic reaction and to examine new epitope mapping strategies meant to improve serum-based allergy diagnostics. Recent epitope mapping approaches have been worthwhile in epitope identification and may increase the specificity of allergy diagnostics by using epitopes predominately recognized by allergic patients in some cases. However, these approaches did not lead to discrimination between clinically relevant and irrelevant epitopes so far, since the polyclonal serum IgE-binding epitope spectrum seems to be too individual, independent of the disease status of the patients. New epitope mapping strategies are necessary to overcome these obstacles. The use of patient-derived monoclonal antibodies instead of patient sera for functional characterization of clinically relevant and irrelevant epitope combinations, distinguished by their ability to induce degranulation, might be a promising approach to gain more insight into the allergic reaction and to improve serum-based allergy diagnostics.
tools or software, although the use of these techniques still has to be proven in future studies. 6, [17] [18] [19] [20] [21] So far, it is impossible to discriminate between clinically relevant and irrelevant epitopes or combinations using current approaches and to use these differences as diagnostic or prognostic markers.
This review will discuss current knowledge, based on a relatively small number of studies investigating linear as well as conformational epitopes and comparing allergic and tolerant patients, and will propose alternative approaches for epitope mapping, focussing on epitope specificity and how this might impact serum-based allergy diagnostics.
| REQUIREMENTS FOR EFFE CTOR CELL DEGRANULATION BY Fcε RI CROSS-LINKIN G
The major requirement for degranulation is the cross-linking of at least two FcεRI receptors. Cross-linking will only be feasible if two FcεRI receptors are spaced apart by 50-240 Å. This range has been defined by using artificial allergens and hence might be somewhat smaller or larger for native allergens. [22] [23] [24] Consequently, the distance of two functional IgE epitopes within one combination is restricted to the required distance of two FcεRI receptors. As an example, possible IgE epitope combinations of Ara h 2.0201, based on a 3D model built with the SWISS-MODEL web portal, are shown in Figure 1 . [25] [26] [27] [28] [29] Residue distances greater than 35 Å, calculated with Chimera, 30 were considered as functional epitope combinations, highlighted on the 3D structure using Schrödinger Release 2018-1 (Maestro, Schrödinger, LLC, New York, NY, 2018). Additionally, at least one epitope of the combination must be recognized with high affinity since the cross-linking has to take place for at least 100 seconds. Moreover, at least 1000 cross-links of FcεRI receptors on the surface of one effector cell have to take place. [31] [32] [33] If all these requirements for FcεRI cross-linking are met, the extent of degranulation is regulated by sIgE concentration, affinity, the ratio of allergen sIgE antibodies compared to total IgE, and the specificity and number of epitopes recognized. 34 These requirements suggest that certain epitope/antibody combinations are only present in allergic and not in tolerant patients. However, basophils from 10% to 20% of the general population do not respond at all due to low expression of syk and/or SHIP-1 resulting in the inhibition of intracellular signalling. [35] [36] [37] [38] Thus, different expression levels might regulate the extent of degranulation.
| FOOD ALLERGENS AS ANTIGENS-

INFLUENCE OF PROCESSING AND DIGESTION
Food allergens are modified by processing during industrial manufacturing or food preparation. 39 After processing, a fraction of these antigens will enter the buccal mucosa unaltered and the remainder will be reprocessed by human digestion before entering the tissue and the bloodstream. [40] [41] [42] They can be modified during industrial manufacturing, which can lead to aggregation or modification of polysaccharide structures or appropriate amino acid residues. Certainly, only a portion of the same allergen is affected. One example is the roasting of peanuts, which usually leads, by Maillard reaction, to the modification of amino acids, especially the hydroxylation of prolines. In the study of The same increase in allergenicity has been observed for the peanut allergen Ara h 1. 43 Processing effects vary, so for example, allergenicity of the hen's egg allergen ovalbumin is decreased upon heat treatment, as shown by patients reacting to raw hen's egg, but not to cooked ones. 45 Modification by heating has also been observed for the cow's milk, with allergens α-and ß-lactalbumin tending to aggregate upon heat treatment although caseins stay unaffected. Knowledge of these features might help to predict the potential allergenicity of proteins even though different conditions of one processing method will have a great impact.
After ingestion, a part of the allergen enters the buccal mucosa and subsequently the bloodstream without being digested; however, as demonstrated in studies with peanut, gastric processing seems to further enhance the uptake and degranulation. 40, 42 The influence of digestion on food allergens has been estimated in several studies and is dependent on the allergen structure. Stable proteins, including Ara h 2 and ovalbumin, remain unaffected by low pH and proteolysis, 47 whereas Ara h 1 and 3, more labile proteins, are fragmented by pepsin.
Upon entering the gut, peptides derived from digestion tend to aggregate due to the basic pH in the gut, [48] [49] [50] 10, 56 A large drawback of these approaches is their failure to detect alterations in allergens caused by post-translational modifications or processing, and specific antibodies can only be detected against single epitopes and never in combination with others. Additionally, the assignment of mimotopes to surface patches of an allergen is solely based on in silico approaches and thus hampers the reliability of the outcome. Although mimotope mapping has been performed for a few allergens with conclusive functional results, 10, 57, 58 it still has to be in context with inhibition and mutation studies using the full-length protein. The general limitation is the requirement of a high-resolution structure for the allergen of interest, constraining a broad application of this approach. Admittedly, mass spectrometry can be used to investigate the influence of post-translational modification using native proteins, and X-ray crystallography to detect epitope combinations. Co-crystallization studies have been performed with murine monoclonal IgG antibodies being able to reduce binding of human polyclonal IgE. [59] [60] [61] [62] Continuatively, co-crystallization has been carried out using monoclonal IgE antibodies generated by combinatorial heavy and light chain libraries of allergic patients. However, it has not been proven whether these antibodies also occur naturally. 63, 64 Information from these studies can help in understanding the features being responsible for allergenicity and in defining critical amino acids more precisely. This knowledge can support the creation of more accurate serum-based diagnostics by modifying critical amino acids recognized by clinically non-relevant IgE antibodies. Moreover, it will give the opportunity to develop hypoallergenic variants for immunotherapy and better (IgE) epitope prediction tools. 65 However, the co-crystallization of polyclonal serum antibodies bound to the allergen of interest is an almost insuperable bottleneck, making X-ray crystallography a more theoretical approach for conformational epitope mapping. These obstacles might be overcome by human-derived monoclonal (IgE) antibodies.
| DISCRIMINATION BETWEEN PERSISTENCE AND TRAN SIENCE BY ME ANS OF IgE -BINDING EPITOPES
Most cow's milk allergic children outgrow their allergy by 3-4 years of age, although 15% remain allergic. In comparison, HEA arises later in childhood and 34% of these children will retain a persistent allergy. 66 Persistence has been studied through analysis of the epitope recognition pattern in patient sera. In CMA, persistent allergy was clearly associated with multiple IgE-binding epitopes on α S1 -, α S2 -, κ-casein, α-, and ß-lactalbumin as these were not recognized by 70, 71 In short, these data favour the use of epitopes to predict persistence and to discriminate between transience and persistence more precisely.
| DISCRIMINATION BETWEEN ALLERGY AND TOLERANCE BY MEANS OF IgE-BINDING EPITOPE S
For allergies less likely to be outgrown, identification of epitopes/antibodies discriminating between tolerance and allergy is essential to EHLERS ET AL.
avoid unnecessary food elimination therapies. In cases of peanut allergy, tolerant patients appeared to recognize the same IgE-binding epitope spectrum on Ara h 2 (linear epitopes) as allergic patients, although individual allergic patients recognized a higher number of different epitopes with higher IgE titres. 72 By means of the two key marker epitopes Ara h 2_10 (aa [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] and Ara h 2_18 (aa 52-66), allergic patients were correctly diagnosed with a sensitivity of 70% and a specificity of 60%. Sensitivity and specificity rose to, respectively, 90% and 95% by adding the IgE-binding epitopes Ara h 1_16
(aa [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] and Ara h3_140 (aa 418-432), which were recognized by few allergic patients. 72 In comparison, the sensitivity and specificity of intact Ara h 2 were defined as, respectively, 60%-100% and 60%-96%, showing no advantage using these two key marker epitopes. 73 Meanwhile, the conformational IgE-binding epitope pattern of Gly m 4 showed no correlation with clinical reactivity at all. 74 The impact of linear or conformational epitopes remains restricted in terms of ruling out tolerance or confirming allergy, as tolerant patients recognize the same epitope spectrum, although less frequently. In summary, to date, no clear discrimination between allergic and tolerant patients is feasible based on the detection of epitopes.
| SEVERITY PREDICTION OF AN ALLERGIC REACTION BY MEANS OF IgE-BINDING EPITOPES
Several studies have been performed to predict the severity of an allergic reaction by using explicit or multiple IgE-binding epitopes of one or multiple allergenic components. To assess whether the severity of allergic reactions towards peanut is related to the type and number of epitopes recognized, patients with different symptoms (ranging from mild to severe and a sIgE level >14 kU/L) have been studied. 9 Patients suffering from severe symptoms recognized fewer linear epitopes than patients with mild symptoms, suggesting that specific epitopes may be more relevant than the quantity of epitopes recognized.
This may relate to the requirements for effector cell degranulation or suggest a greater relevance for conformational epitopes. However, conformational B-cell epitopes did not contribute to severe symptoms as assessed by mimotopes mapped to the surface of Ara h 2 and 6. In contrast, when investigated using a competition assay, the allergic group exhibited low and high-affinity antibodies. 76 Low Based on IgE-binding pattern prior starting AIT, a prediction model for safety (=number of adverse reaction while AIT) and efficacy (=time required to achieve desensitization) was developed. The model included two sets of 16 IgE-binding regions of caseins to be associated with safety and efficacy. 106 In further milk and peanut AIT trials, the induction of a hyporesponsive state of basophils was observed. This state was additionally applicable for hen's egg-sensitized patients in a population of peanut allergic patients. 107, 108 A possible explanation is the IgG epitope-spe- 
| DIFFERENT EPITOPE MAPPING APPROACHES MAY INCREASE THE CONTRIBUTION OF ALLERGEN-SPECIFIC B -CELL EPITOPES
To overcome the limitations described in the previous paragraphs, requirements for degranulation should be considered. Since crosslinking of at least two FcεRI receptors is crucial, an allergic subject must feature IgE antibodies recognizing two epitopes with a distinct distance on the cell surface, of which at least one with high affinity. 22 In contrast, two IgE antibodies, with low affinity recognizing a relevant epitope combination, or one IgE-antibody recognizing one epitope of a relevant epitope combination may occur in a tolerant patient without causing degranulation. Current IgE serum-based diagnostics cannot discriminate between high-and low-affinity antibodies, impeding the discrimination between relevant and irrelevant epitopes or combinations. Instead of polyclonal sera, a more distinct
characterization of specific epitopes might be feasible by using human monoclonal antibodies. This approach may also give precise information about epitope specificity and affinity (illustrated in Figure 2 ). Furthermore, co-crystallization of an epitope-specific monoclonal antibody or a ScFv with an allergen of interest is significantly more likely to be successful compared to the use of polyclonal sera, which offers a chance to detect authentic conformational epitopes.
Since IgE-producing B-cells in blood are scarce, the first studies with IgE monoclonal antibodies were performed with murine allergen-specific antibodies, originally IgG but subsequently heterologously expressed as IgE antibodies. 34 In addition, human monoclonal IgE antibodies were obtained by construction of phage display ScFv hybrid libraries with allergic donor-derived epsilon heavy chain and synthetic variable regions for the light chain. 114, 115 However, these approaches did not address the whole allergenspecific antibody repertoire of one subject. In studies by Hoh et al F I G U R E 2 Defining differences in epitope-binding pattern of tolerant but sensitized and allergic patients are hampered by similar appearing polyclonal antibody repertoires (parts of the graphic from Servier Medical Art by Servier-http://smart.servier.com/). A, The polyclonal repertoires in sera of tolerant but sensitized and allergic patients seem to be similar but only antibodies out of the repertoire from allergic patients are able to induce an allergic reaction. B, The use of monoclonal antibodies enables a more extensive characterization of individual antibodies responsible for the allergic reaction. Tolerant as well as allergic patients can possess antibodies with similar epitope specificities but with different affinity.
of different allergen-specific isotypes remains unclear. Finally, we recommend the inclusion of tolerant and allergic patients sensitized to the same allergen for the generation of specific monoclonal antibodies. Monoclonal antibody repertoires within these two groups may allow the discovery of differences in epitope specificity and affinity. To ensure the capture of B-cells producing antibodies with comparable affinity and epitope specificity as the polyclonal serum repertoire, the plasma of the patients should be saved and analysed for their epitope recognition spectrum and affinity. In addition, competition assays with monoclonal antibodies and serum antibodies can be performed to detect differences in affinity.
Potentially, these findings can contribute not only to the improvement of food allergy diagnostics but also monitoring of allergy immunotherapy. This epitope mapping strategy will be restricted by the absence of short and long-living plasma cells in the blood as well as the still discussed presence of IgE memory B-cells. 77 77 Another aspect to take into account is the expression of the low-affinity FcεRII (CD23) on non-allergen specific translational B-cells in the blood stream. 123, 124 The cells can bind allergen-specific IgE antibodies leading to the selection of B-cells irrelevant for allergy. Non-specific antibodies can be excluded through a specificity check, such as performing an ELISA coated with the allergen of interest.
Another approach to enlarging the impact of B-cell epitopes in food allergy diagnostics might be the development of improved computational epitope prediction. To exceed the abilities of already available prediction software or webtools for B-cell epitopes, computational approaches for predicting allergenic functionality must meet, as described above, the special requirements for degranulation, for example, the defined distance between two epitopes. Before using these distances as a basis for prediction, they should be estimated by natural and not, as now, by artificial allergens. Furthermore, new algorithms must consider the potential oligomerization of allergenic proteins, since this can increase the number of possible epitope combinations for triggering effector cell degranulation.
| CONCLUSION
The use of monoclonal antibodies might be a powerful tool to define the allergen-specific antibody repertoire of tolerant and allergic patients more precisely in terms of epitope specificity, affinity, and feasible epitope combinations. This will produce more knowledge about the reasons some sensitized patients can tolerate an allergen with no symptoms while others will experience a (severe) allergic reaction. Differences in antibody repertoires can lead to improved sIgE measurement by modifying critical amino acids recognized by clinically irrelevant antibodies and thus preventing false-positive test results and avoiding burdensome food challenges. In addition, the characterization of allergen-specific antibody repertoires during immunotherapy may lead to a better understanding of the underlying mechanism.
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